Marplan® (isocarboxazid) titration
Marplan® (isocarboxazid) is supplied in bottles of 100 peach-colored, scored tablets each containing 10 mg of isocarboxazid (NDC 30698-032-01).
For maximum therapeutic effect, the dosage of Marplan must be individually adjusted on the basis of careful observation of the patient.
Dosage should be started with one tablet (10 mg) of Marplan twice daily.
If tolerated, dosage may be increased by increments of one tablet (10 mg) every 2 to 4 days to achieve a dosage of four tablets daily (40 mg) by the end of the first week of treatment.
Dosage can then be increased by increments of up to 10 mg/week, if needed and tolerated, to a maximum recommended dosage of 60 mg/day. Daily dosage should be divided into two to four dosages.
After maximum clinical response is achieved, an attempt should be made to reduce the dosage slowly over a period of several weeks while achieving the therapeutic response.
Beneficial effect may not be seen in some patients before 3 to 6 weeks. If no response is obtained by then, continued administration is
unlikely to help.
Because of the limited experience with systematically monitored patients receiving Marplan at the higher end of the currently recommended dose range of up to 60 mg/day, caution is indicated in patients for whom a dose of 40 mg/day is exceeded.
Please see Full Prescribing Information including BOXED WARNINGS regarding increased risk of suicidality in children and adolescents. MAO-Inhibitors are contraindicated with certain drugs. Potential hypertensive crises may occur with foods that contain tyramine. As with all antidepressants, patients should be observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of treatment.
|